Circulating microRNAs, miR-143, miR-100 and miR-92, as non-invasive biomarkers for bladder cancer diagnosis /
Taghried Mahmoud Ibrahim Hellaly
Circulating microRNAs, miR-143, miR-100 and miR-92, as non-invasive biomarkers for bladder cancer diagnosis / ميكرو أر إن إيه 143: ميكرو أر إن إيه 100و ميكرو أر إن إيه 92 كدلائل حيوية غير غازية لتشخيص سرطان المثانة Taghried Mahmoud Ibrahim Hellaly ; Supervised Tarek Mohamed Motawi , Sherine Maher Rizk , Ihab abdel Rahman Ibrahim - Cairo : Taghried Mahmoud Ibrahim Hellaly , 2017 - 121 P. : charts ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Chemistry
The application of microRNAs (miRNAs) as potential biomarkers and therapy targets has been widely investigated in many kinds of cancers. Recent advantages of serum miRNAs open a new realm of possibilities for noninvasive diagnosis and prognosis of bladder cancer (BC). The aim of our study was to identify plasma miR-92a, miR-100 and miR-143 expression signatures in patients with BC to introduce new markers for establishing BC diagnosis and prognosis. Blood samples were collected from 70 BC patients and 62 controls. Expression of 3 target miRNAs (miR-92a, miR-100 and miR-143) was measured using a quantitative real-time PCR method. The results were correlated with clinicopathological data and analyzed. Plasma levels of miR-92a, miR-100, and miR-143 were significantly lower in BC patients than in the control group. Receiver operator characteristic (ROC) analysis revealed that the sensitivity and specificity values of miR-92a were 97.1% and 76.7%, respectively, with a cut-off value of 0.573. The sensitivity and specificity values of miR-100 were 90% and 66.7%, respectively, with a cut-off value of 0.644. The sensitivity and specificity values of miR-143 were 78.6% and 93.3%, respectively, with a cut-off value of 0.164. This study explores the existence of specific plasma miRNAs as early diagnostic biomarkers for BC in Egyptian patients; and these findings suggest that plasma miR-92a, miR-100 and miR-143 could be a promising novel circulating biomarkers in clinical detection of BC
Bladder cancer MicroRNA Molecular marker
Circulating microRNAs, miR-143, miR-100 and miR-92, as non-invasive biomarkers for bladder cancer diagnosis / ميكرو أر إن إيه 143: ميكرو أر إن إيه 100و ميكرو أر إن إيه 92 كدلائل حيوية غير غازية لتشخيص سرطان المثانة Taghried Mahmoud Ibrahim Hellaly ; Supervised Tarek Mohamed Motawi , Sherine Maher Rizk , Ihab abdel Rahman Ibrahim - Cairo : Taghried Mahmoud Ibrahim Hellaly , 2017 - 121 P. : charts ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Chemistry
The application of microRNAs (miRNAs) as potential biomarkers and therapy targets has been widely investigated in many kinds of cancers. Recent advantages of serum miRNAs open a new realm of possibilities for noninvasive diagnosis and prognosis of bladder cancer (BC). The aim of our study was to identify plasma miR-92a, miR-100 and miR-143 expression signatures in patients with BC to introduce new markers for establishing BC diagnosis and prognosis. Blood samples were collected from 70 BC patients and 62 controls. Expression of 3 target miRNAs (miR-92a, miR-100 and miR-143) was measured using a quantitative real-time PCR method. The results were correlated with clinicopathological data and analyzed. Plasma levels of miR-92a, miR-100, and miR-143 were significantly lower in BC patients than in the control group. Receiver operator characteristic (ROC) analysis revealed that the sensitivity and specificity values of miR-92a were 97.1% and 76.7%, respectively, with a cut-off value of 0.573. The sensitivity and specificity values of miR-100 were 90% and 66.7%, respectively, with a cut-off value of 0.644. The sensitivity and specificity values of miR-143 were 78.6% and 93.3%, respectively, with a cut-off value of 0.164. This study explores the existence of specific plasma miRNAs as early diagnostic biomarkers for BC in Egyptian patients; and these findings suggest that plasma miR-92a, miR-100 and miR-143 could be a promising novel circulating biomarkers in clinical detection of BC
Bladder cancer MicroRNA Molecular marker